Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in ...
Clinical Trial: Phase 1b/3 Targeted Alpha-Emitter PRRT RYZ101 (Ac225 ...
Anti-tumor activity of RYZ101 (Ac-225 DOTATATE) in somatostatin ...
Clinical Trials - Targeted Alpha-Emitter PRRT RYZ101 (Ac225) - Ronny ...
ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2 ...
RYZ101 + SoC for Small Cell Lung Cancer Clinical Trial 2023 | Power
RYZ101 (Ac-225 DOTATATE) Opportunity beyond Gastroenteropancreatic ...
Study on RYZ101 for Patients with Advanced Gastroenteropancreatic ...
RYZ101 for Neuroendocrine Tumor Disease Clinical Trial 2023 | Power
OA13.03 RYZ101 (225Ac-DOTATATE) + Carboplatin +... : Journal of ...
RayzeBio Announces Issuance of Two Patents for RYZ101 (225Ac-DOTATATE ...
ACTION-1: Study Initiates Treatment With RYZ101 in SSTR+ ...
GEP-NETs - RayzeBio
Posters & Presentations - RayzeBio
41亿美元!BMS收购RayzeBio,艾博兹拥有大中华区权益医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
RayzeBio Advances RYZ101, a Targeted Radiopharmaceutical Delivering ...
艾博兹医药:硬“核”创新,引领靶向治疗新篇章 近年来,在 精准医疗 理念和趋势的引领下,得益于放射性核素制备、高通量分子库筛选和定点偶联等技术 ...
BMS斥资41亿进军核药重启3期临床,RYZ101或成潜在全球首款_摩熵医药
成立3年、41亿美金卖身,核药赛道最大并购案诞生背后-蓝鲸财经
招股书导读:RayzeBio,研发肿瘤靶向RDC药物 - 知乎
生物医药企业RayzeBio上市:市值13亿美元 路演PPT曝光_腾讯新闻
Dosimetry Results from the Phase 1b/3 ACTION-1 Trial of [225Ac]Ac ...
RYZ101(RayzeBio)|Chiku-note.
225Ac-DOTATATE (RYZ101) dosimetry results from Part 1 of the ACTION-1 ...
'방사성의약품' 레이즈바이오, "3.11억弗" 나스닥 IPO - 바이오스펙테이터
Exploring the Latest RDC Deal by RayzeBio: A Guide to Rapidly Accessing ...
恒瑞给了核药市场一个「小震撼」 - 知乎
41亿美元!BMS溢价收购RayzeBio医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
极速狂飙,三年即上市的核药超新星--RayzeBio - 知乎
Clinical Trials - Targeted Alpha-Emitter PRRT RYZ101/RYZ401 - Ronny ...
Rayzebio, Inc. (Rayzebio, Inc.) - 药物管线_专利_临床试验_投融营收_最新药物:RYZ-101,RYZ ...
13.5亿美元!BMS子公司引进靶向核药OncoACP3
LOGO
BMS Lays Out Strategic Direction in Nuclear Medicine
9月:Biotech企业上市融资规模新高,重返加息前水平 - 知乎
97亿!核药今年最大合作刚刚诞生-动脉网
Quarkmed (@Quarkmed_CRO) / Posts / X
放射药公司RayzeBio完成1.6亿美元D轮融资,累计融资4.18亿美元医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Somatostatin Radiotherapy Advances
Actinium-225: The "Alpha Warrior" Ushering in a New Era of ...
BMS杀入核药领域医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
RayzeBio IPO Presentation Deck | Slidebook.io
RayzeBio:D轮融资1.6亿美元,专注放射性靶向肿瘤治疗药_腾讯新闻
Pipeline - RayzeBio
RayzeBio IPO presentation — September 2023 · 41 slides | Slidebook
IPO Update: RayzeBio Readies $245 Million IPO (RYZB) | Seeking Alpha
Theranostics: recent developments in neuroendocrine tumors - memoinOncology
BMS斥资41亿进军核药重启3期临床,RYZ101或成潜在全球首款_摩熵医药(原药融云)
RayzeBio on LinkedIn: Highlighting our radiopharmaceutical programs ...
#bms #rayzebio #radiotherapy #radiopharmaceuticals #targetedtherapy # ...
#aacr2023 #aacr23 #targetedtherapy #radiationoncology # ...
生物医药企业RayzeBio登陆纳斯达克医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
【RYZB】RayzeBio、IPO から買収されるまでの流れ | Zoomy (ズーミー)
抗真菌药Rezzayo已在美上市,可用于治疗念珠菌血症、侵袭性念珠菌病-上市-医保-临床适应症-香港济民药业
RYZ-101(RYZ-101) - 药物靶点:SSTR2_在研适应症:类癌,功能性内分泌肿瘤,胃肠胰神经内分泌肿瘤_专利_临床_研发
必治妥施貴寶將以41億美元收購RayzeBio | 鉅亨網 - 美股雷達
Neuroendocrine tumours (NETs) | Open Medscience
RYZ-101 - Drug Targets, Indications, Patents - Synapse
Nike RYZ 365 BQ4153-101 ab 63,00
五大藥廠大戰核藥時代!RLT(放射性配體療法)產業佈局全解析 - 藥時事 Drugnews (@drugnews) | Dcard
Bristol Myers Squibb Expands Portfolio with Purchase of Leading ...
Yahoo!オークション - 【NIKE ナイキ/RYZ 365 2 WMNS/CU4874-101】高級...
Buty NIke RYZ 365 (BQ4153-101) WHITE/PISTACHIO FROST-PHOTON DUST-BLACK ...